Henrik Wiggers

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Anders Jorsal
  • Caroline Kistorp, Department of Internal Medicine and Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • ,
  • Pernille Holmager, Department of Internal Medicine and Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • ,
  • Rasmus Stilling Tougaard
  • Roni Nielsen
  • Anja Hänselmann, Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • ,
  • Brian Nilsson, Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark.
  • ,
  • Jacob Eifer Møller, Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • ,
  • Jakob Hjort
  • Jon Rasmussen, Department of Internal Medicine and Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • ,
  • Trine Welløv Boesgaard, Steno Diabetes Center , Gentofte , Denmark.
  • ,
  • Morten Schou, School of Pharmaceutical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • ,
  • Lars Videbaek, Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • ,
  • Ida Gustafsson, Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark.
  • ,
  • Allan Flyvbjerg
  • ,
  • Henrik Wiggers
  • Lise Tarnow, Steno Diabetes Center , Gentofte , Denmark.

AIMS: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.

METHODS AND RESULTS: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).

CONCLUSION: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

Original languageEnglish
JournalEuropean Journal of Heart Failure
Volume19
Issue1
Pages (from-to)69-77
ISSN1388-9842
DOIs
Publication statusPublished - 2017

See relations at Aarhus University Citationformats

ID: 104275369